Next-generation biomanufacturing market worth $43.16 billion by 2030

JERSEY CITY, NJ, June 14, 2022 /PRNewswire/ — InsightAce Analytic Pvt. announces the publication of a market assessment report on the ” Global Next Generation Biomanufacturing Market (Medical applications (monoclonal antibodies, hormones, vaccines, recombinant proteins and other applications), products (continuous upstream biomanufacturing products, single-use upstream biomanufacturing products and downstream biomanufacturing products), workflows (upstream biomanufacturing and Downstream), End-User (Biopharmaceutical Companies, CMOs (Contract Manufacturing Organizations)/CDMOS (Contract Development and Manufacturing Organizations) and Research Institutes) – Trends, Industry Competitive Analysis, Revenue and forecast until 2030.”

InsightAce analytics logo

According to the latest research from InsightAce Analytic, the global next-generation biomanufacturing market is valued at US$19.85 billion in 2021, and it is expected to reach US$43.16 billion by 2030 growing at a CAGR of 9.3% over the forecast period 2022-2030.

Request for sample pages: https://www.insightaceanalytic.com/request-sample/1261

Next-generation biomanufacturing services enable the development and manufacture of a wide range of products with the highest level of quality than first-generation biomanufacturing products. These services focus on single-use technologies such as single-use bio-containers and single-use bioreactors, enabling better process flexibility and efficiency.

Factors such as advanced medical technologies, high demand for gene and cell therapy products, increasing government effects to develop more efficient next-generation bioprocessing units, high prevalence of chronic and genetic diseases, increasing geriatric population, growing awareness of the benefits of next-generation bio-manufacturing, availability of well-established healthcare infrastructure are expected to witness significant market growth over the forecast years. The development and production of drugs and materials involves complex procedures and requires special equipment. Therefore, to face such difficulties, biopharmaceutical companies are opting for advanced biomanufacturing solutions to increase production quality and efficiency, which is expected to improve the production of next-generation biomanufacturing products in the years to come. come.

On the other hand, factors such as lack of skilled professionals and complexity of processing operations may limit the market adoption during the forecast period.

At the regional level, North America dominated this market in 2021 and is expected to dominate the next-generation biomanufacturing market over the forecast period (2022-2030), owing to well-developed biopharmaceutical industries, rapid adoption of modern technologies and the increasing use of innovative technologies.

Find out before you buy: https://www.insightaceanalytic.com/enquiry-before-buying/1261

Major market players operating in the next generation biomanufacturing market include Applikon Biotechnology B.V. (Netherlands), bbi-biotech GmbH (Germany), Danaher Corporation (USA), Eppendorf AG (Germany), Esco Group of Companies (USA), GEA Group Aktiengesellschaft (Germany), Meissner Filtration Products, Inc. (USA), Merck KGaA (Germany), PBS Biotech, Inc. (United States), Pierre Guérin (France), Sartorius AG (Germany), Shanghai Bailun Biotechnology Co. Ltd. (China), Solaris Biotechnology Srl. (Italy), Thermo Fisher Scientific Inc. (USA), ZETA GmbH (Austria), among others.

Main market developments:

  • In August 2021, PBS Biotech (USA) secured its highest funding round with BroadOak Capital Partners to expand its product offerings and capabilities. The budget is used to expand PBS’ product offerings and capabilities and meet demand for cell therapies.

  • In February 2021Merck (Germany) in partnership with Alteogen, Inc. (South Korea), a company providing late-stage CDMO services through Merck’s BioReliance end-to-end solutions. Alteogen has selected Merck to develop and produce recombinant biologics to develop and clinically evaluate next-generation monoclonal antibody therapies.

  • In November 2020, Merck (Germany) collaborated with Transcenta, a biotherapeutics company, to implement and advance the continued manufacturing of therapeutic proteins.

Market segments

Global Next Generation Biomanufacturing Market, By Medical applications2022-2030 (value in billion US dollars)

  • Monoclonal antibodies

  • Hormones

  • Vaccines

  • Recombinant proteins

  • Other Apps

Global Next Generation Biomanufacturing Market, By Some products2022-2030 (value in billion US dollars)

  • Upstream continuous biomanufacturing products

  • Single-use upstream biomanufacturing products

  • Downstream biomanufacturing products

Global Next Generation Biomanufacturing Market, By Workflow2022-2030 (value in billion US dollars)

Global Next Generation Biomanufacturing Market, By end users2022-2030 (value in billion US dollars)

  • Biopharmaceutical companies

  • CMO (Contract manufacturing organizations)/CDMO (Contract Development and Manufacturing Organization)

  • Research institutions

Global Next Generation Biomanufacturing Market, By Region2022-2030 (value in billion US dollars)

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

North America Next Generation Biomanufacturing Market, By Country2022-2030 (value in billion US dollars)

European Next Generation Biomanufacturing Market, by Country2022-2030 (value in billion US dollars)

  • Germany

  • France

  • Italy

  • Spain

  • Russia

  • Rest of Europe

Asia Pacific Next Generation Biomanufacturing Market, By Country2022-2030 (value in billion US dollars)

  • India

  • China

  • Japan

  • South Korea

  • Australia & New Zealand

Latin America Next Generation Biomanufacturing Market, By Country2022-2030 (value in billion US dollars)

  • Brazil

  • Mexico

  • Rest of Latin America

Middle East & Africa Next-Generation Biomanufacturing Market, by Country2022-2030 (value in billion US dollars)

Why buy this report:

  • Receive a comprehensive outlook analysis of the global next-generation biomanufacturing market

  • To receive industry insights and future next-generation biomanufacturing market trends

  • Analyze Next Generation Biomanufacturing Market Drivers and Challenges

  • For insight into Next Generation Biomanufacturing Market Size (Value in Billion US$) Forecasted to 2030

  • Significant Investments, Mergers, and Acquisitions in the Next Generation Biomanufacturing Market Industry

For customization @ https://www.insightaceanalytic.com/customization/1261

Other related reports published by InsightAce Analytics:

Global iPSC Manufacturing Services Market

Global Biopharmaceutical Excipient Manufacturing Market

Global Allogeneic Cell Therapy Manufacturing Market

Global mRNA Synthesis and Manufacturing Services Market

About Us:

InsightAce Analytic is a market research and consulting company that empowers clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market intelligence and competition to grow businesses. We help our clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in delivering syndicated and customized market intelligence reports with in-depth analysis with key market insights in a timely and cost effective manner.

Contact us:

InsightAce Analytics Pvt. ltd.
Such. : +1 718 593 4405
Email: [email protected]
Site visit: www.insightaceanalytic.com
Follow us on LinkedIn @ bit.ly/2tBXsgS
Follow us on Facebook @ bit.ly/2H9jnDZ

Quote

Quote

View original content: https://www.prnewswire.com/news-releases/next-generation-biomanufacturing-market-worth-43-16-billion-by-2030—exclusive-report-by-insightace-analytic – 301567377.html

SOURCE InsightAce Analytics Pvt. ltd.